NHC
National HealthCare Corporation
$239.24
-1.47% 2026-10-19
Health CareS&P 600
NHCSPY
1W
+4.1%
1M
+8.0%
3M
+9.1%
6M
+44.5%
YTD
+76.3%
1Y
+99.1%
Grades vs sector
Momentum94th pct in sectorA
Momentum
94th pct in sector
12-1 return: +86.5%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth52nd pct in sectorC+
Growth
52nd pct in sector
Revenue growth (YoY): +8.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value18th pct in sectorD
Value
18th pct in sector
Forward E/P: 0.2% · EBITDA/EV: 5.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability56th pct in sectorB-
Profitability
56th pct in sector
Profit margin: +9.0% · Return on equity: +13.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Held by 1 of 3 live models: Momentum Blend.
Momentum Blend
4.3% of the book · Core sleeve
HeldMomentum Top 15not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Key stats
Market cap$3.7B
P/E (trailing)26.9
P/E (forward)556.4
52-week range118.14 – 247.79
Revenue growth (YoY, latest qtr)+8.8%
Dividend yield1.10%
Analyst consensusNone
Mean price target–
Valuation & fundamentals
Bottom line
Leans undervalued
Model read-out from the numbers below, not advice. Score +2 (DCF counts double).
▲DCF (base case)above the price by 36%
▼Forward P/E vs sector556.4x vs median 17.6x
▲Piotroski F-score8/9
▲Altman Z7.8 (safe)
▲Net debt / EBITDA-0.8x
Discounted cash flow
Bear
$192
-20%
growth 5% · disc. 8.3% · term. 2.0%
Base
$324
+36%
growth 10% · disc. 7.3% · term. 2.5%
Bull
$550
+130%
growth 13% · disc. 6.3% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 4% a year for 10 years.
Implied
+4%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
-4%/yr
Revenue, last 3 yrs
+12%/yr
Revenue, last 5 yrs
+8%/yr
Same inputs as the DCF above: trailing free cash flow 0.1B, 7.3% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.61 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 44th pct
26.9×cheaper
Forward P/E
pricier
sector median 17.6× · 99th pct
556.4×pricier
EV / EBITDA
pricier
sector median 15.8× · 64th pct
18.9×pricier
Price / sales
cheaper
sector median 3.1× · 38th pct
2.4×cheaper
Price / book
cheaper
sector median 3.5× · 48th pct
3.3×cheaper
FCF yield
pricier
sector median 4.1% · 45th pct
3.9%pricier
Forward EPS $0.43 vs trailing $8.89 (-95% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
9.3%
FCF margin
9.4%
Net margin
9.0%
Return on equity
12.5%
Return on invested capital
11.5%
Net debt / EBITDA
-0.8×
Current ratio
1.9×
Interest cover
56.6×
Cash conversion (OCF/NI)
1.3×
Piotroski F-score 8/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 7.8 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
No analyst targets available.
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $1.5B | $120.0M | $148.6M |
| 2024 | $1.3B | $101.9M | $79.7M |
| 2023 | $1.1B | $66.8M | $83.3M |
| 2022 | $1.1B | $22.4M | $-21.5M |
| 2021 | $1.1B | $138.6M | $23.0M |
| 2020 | $1.0B | $41.9M | $181.4M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +11.8%.
Earnings
Next report: 2026-11-06 · before open
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2015-05-07 | 0.90 | 0.77 | -14.6% |
| 2015-02-20 | 0.93 | 0.88 | -5.5% |
| 2014-11-06 | 0.85 | 0.75 | -11.3% |
| 2014-08-06 | 0.76 | 0.72 | -4.8% |
| 2014-05-08 | 0.98 | 0.78 | -20.2% |
| 2013-11-05 | 1.03 | 1.19 | +15.2% |
| 2013-08-01 | 0.88 | 0.86 | -2.5% |
| 2013-05-08 | 0.67 | 0.82 | +23.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $408.0M | +8.8% |
| 2026-03-31 | $381.8M | – |
| 2025-12-31 | $386.5M | – |
| 2025-09-30 | $382.7M | – |
| 2025-06-30 | $374.9M | – |
Recent dividends
2026-09-30: $0.670 · 2026-06-30: $0.670 · 2026-03-31: $0.640 · 2025-12-31: $0.640 · 2025-09-30: $0.640 · 2025-06-30: $0.640 · 2025-03-28: $0.610 · 2024-12-30: $0.610
Insider trades
Dodson Vicki L
$1.1M
Sr.VP Patient Srvcs · 2026-09-22
SELL$1.1M
Kidd Brian F
$1.5M
SVP, CFO · 2026-09-11
SELL$1.5M
Mccreary Josh A
$127.2K
Senior VP & General Counsel · 2026-09-10
SELL$127.2K
Mccreary Josh A
$176.6K
Senior VP & General Counsel · 2026-09-10
SELL$176.6K
Mccreary Josh A
$290.6K
Senior VP & General Counsel · 2026-09-10
SELL$290.6K
Mccreary Josh A
$15.3K
Senior VP & General Counsel · 2026-09-10
SELL$15.3K
Flatt Ben Anderson Sr
$222.5K
Senior VP & CIO · 2026-08-28
SELL$222.5K
Flatt Ben Anderson Sr
$227.0K
Senior VP & CIO · 2026-08-25
SELL$227.0K
Gifford David R.
$401.0K
Director · 2026-08-25
SELL$401.0K
Flatt Ben Anderson Sr
$237.0K
Senior VP & CIO · 2026-08-20
SELL$237.0K
Flatt Ben Anderson Sr
$237.2K
Senior VP & CIO · 2026-08-19
SELL$237.2K
Flatt Stephen Fowler
$355.6K
Director, CEO · 2026-08-19
SELL$355.6K
News
National HealthCare (NHC) Stock Trades Below Fair Value On A 289% Run
Simply Wall St. · Oct 18
Raymond James Initiates Coverage on National Healthcare With Outperform Rating, $20 Price Target
MT Newswires · Oct 13
National Healthcare Insider Sold Shares Worth $1,087,650, According to a Recent SEC Filing
MT Newswires · Sep 24
NHC Debuts a New Model for Retail Wellness with Brentwood Flagship Store
Business Wire · Sep 17
National Healthcare Insider Sold Shares Worth $609,669, According to a Recent SEC Filing
MT Newswires · Sep 14
National Healthcare Insider Sold Shares Worth $1,537,694, According to a Recent SEC Filing
MT Newswires · Sep 14
National Healthcare Insider Sold Shares Worth $1,593,000, According to a Recent SEC Filing
MT Newswires · Sep 02
National Healthcare Insider Sold Shares Worth $355,620, According to a Recent SEC Filing
MT Newswires · Aug 20
Stats refreshed 2026-10-19 17:47:08 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.